Can Ivermectin Treat Cancer?

The Short Answer

Ivermectin is an antiparasitic medicine that has been used in people for decades for certain parasitic infections. Researchers have also investigated whether it could have anticancer effects.

In laboratory experiments, ivermectin has affected the growth and survival of several types of cancer cells. Animal experiments have also produced findings interesting enough to support further investigation.

But this is where an important distinction has to be made: a drug can kill cancer cells in a laboratory and still fail as a cancer treatment in humans.

At present, ivermectin is not an established cancer therapy, and high-quality human evidence showing that it improves cancer outcomes is lacking.

Can Ivermectin Treat Cancer? What the Evidence Actually Shows

The scientific interest in ivermectin is real. It is not simply an internet invention.

Preclinical studies have reported that ivermectin can affect biological processes involved in cancer-cell growth and survival. A study published in Cancer Chemotherapy and Pharmacology tested ivermectin across 28 malignant cell lines and also investigated its effects in tumor-bearing mice.

The researchers found enough anticancer activity to argue that ivermectin deserved clinical investigation as a potential repurposed cancer drug.

That conclusion matters—but so does the wording. The research supported clinical testing. It did not demonstrate that ivermectin had already become an effective cancer treatment for patients.

Why aren’t laboratory results enough?

Laboratory cancer research is designed to identify possibilities. Researchers can expose cancer cells directly to a drug and measure what happens.

The human body is much more complicated.

Researchers need to know whether concentrations that affect cancer cells can be achieved safely in people, how the drug behaves inside the body, whether particular cancers are more sensitive than others, and whether the treatment actually improves outcomes that matter to patients.

Many compounds that look encouraging in preclinical experiments never become successful cancer treatments.

What Do We Know From Human Cancer Research?

This is currently the biggest weakness in the ivermectin cancer claim.

A 2025 review in Current Oncology Reports examined ivermectin’s potential role in cancer treatment. The authors described substantial preclinical research but also emphasized the lack of large randomized clinical trials establishing therapeutic benefit in cancer patients.

Without well-designed controlled trials, researchers cannot reliably determine whether ivermectin causes tumor responses, delays cancer progression or improves survival.

Early clinical observations can help researchers decide what deserves further study. They cannot provide the same level of evidence as randomized trials designed to test whether a treatment actually works.

Why Is Ivermectin Being Studied for Cancer?

Drug repurposing is a legitimate area of medical research. Instead of developing every cancer drug from scratch, researchers investigate whether medicines already used for other diseases might also affect cancer biology.

Ivermectin is interesting because experimental research suggests that it may influence several cellular pathways involved in cancer-cell proliferation, metabolism and cell death.

Having an existing medicine with known pharmacology can make a drug an attractive research candidate. But prior approval for one disease does not prove effectiveness against another.

An antiparasitic drug becoming a cancer treatment would require cancer-specific clinical evidence just like any other proposed therapy.

Could Taking Ivermectin for Cancer Be Harmful?

The biggest danger is not the existence of ivermectin research. It is turning early research into self-treatment before clinical benefit has been established.

Using ivermectin instead of proven cancer therapy could delay treatment known to improve outcomes.

Dose also matters. The FDA warns that taking large doses of ivermectin can be dangerous and that ivermectin can interact with other medicines. Veterinary ivermectin products are formulated differently and should not be used by people.

Cancer patients may already be receiving chemotherapy, targeted therapy, immunotherapy or other medicines. Adding an unproven drug without the oncology team’s knowledge can introduce unnecessary risks and potential interactions.

What We Still Don’t Know

There are several important unanswered questions.

Researchers still need to establish whether ivermectin has meaningful anticancer activity in humans, which cancer types—if any—might benefit, what dose and schedule would be appropriate, whether effective concentrations can be achieved safely, and whether it works better alone or in combination with established therapies.

Most importantly, properly designed clinical trials need to show whether ivermectin improves meaningful patient outcomes such as tumor response, progression-free survival or overall survival.

Until those questions are answered, ivermectin should be considered an experimental research candidate—not a proven cancer treatment.

Sources

Patel Y, Chawla J, Parmar MS. Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? Current Oncology Reports. 2025. PMID: 40715995. DOI: 10.1007/s11912-025-01704-z.

Juarez M, et al. Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. Cancer Chemotherapy and Pharmacology. 2020. PMID: 32474842. DOI: 10.1007/s00280-020-04041-z.

U.S. Food and Drug Administration. Ivermectin and COVID-19. Regulatory and safety information regarding approved ivermectin uses, dosing risks, drug interactions and veterinary formulations.

Questions for Your Doctor

• Is there credible clinical evidence for ivermectin in my specific type of cancer?
• Are there clinical trials studying drug repurposing for my cancer?
• Could ivermectin interact with any of my cancer treatments or other medicines?
• If I find an experimental cancer treatment online, how can we evaluate the evidence together?